In:
Clinical Cardiology, Wiley, Vol. 46, No. 8 ( 2023-08), p. 950-957
Abstract:
This study aimed to explore the predictive value of CHA 2 DS 2 ‐VASc score for in‐hospital major adverse cardiac events (MACEs) in ST‐elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary artery intervention. Methods A total of 746 STEMI patients were divided into four groups according to CHA 2 DS 2 ‐VASc score (1, 2–3, 4–5, 〉 5). The predictive ability of the CHA 2 DS 2 ‐VASc score for in‐hospital MACE was made. Subgroup analysis was made between gender differences. Results In a multivariate logistic regression analysis model including creatinine, total cholesterol, and left ventricular ejection fraction, CHA 2 DS 2 ‐VASc score was an independent predictor of MACE as a continuous variable (adjusted odds ratio: 1.43, 95% confidence interval [CI]: 1.27–1.62, p 〈 .001). As a category variable, using the lowest CHA 2 DS 2 ‐VASc score of 1 as a reference, CHA 2 DS 2 ‐VASc score 2–3, 4–5, 〉 5 groups for predicting MACE was 4.62 (95% CI: 1.94–11.00, p = .001), 7.74 (95% CI: 3.18–18.89, p 〈 .001), and 11.71 (95% CI: 4.14–33.15, p 〈 .001). The CHA 2 DS 2 ‐VASc score was also an independent risk factor for MACE in the male group, either as a continuous variable or category variable. However, CHA 2 DS 2 ‐VASc score was not a predictor of MACE in the female group. The area under the curve value of the CHA 2 DS 2 ‐VASc score for predicting MACE was 0.661 in total patients (74.1% sensitivity and 50.4% specificity [ p 〈 .001]), 0.714 in the male group (69.4% sensitivity and 63.1% specificity [ p 〈 .001]), but there was no statistical significance in the female group. Conclusions CHA 2 DS 2 ‐VASc score could be considered as a potential predictor of in‐hospital MACE with STEMI, especially in males.
Type of Medium:
Online Resource
ISSN:
0160-9289
,
1932-8737
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2048223-1
Permalink